[go: up one dir, main page]

FR3102041B1 - Sweetener for electronic cigarette liquids - Google Patents

Sweetener for electronic cigarette liquids Download PDF

Info

Publication number
FR3102041B1
FR3102041B1 FR1911826A FR1911826A FR3102041B1 FR 3102041 B1 FR3102041 B1 FR 3102041B1 FR 1911826 A FR1911826 A FR 1911826A FR 1911826 A FR1911826 A FR 1911826A FR 3102041 B1 FR3102041 B1 FR 3102041B1
Authority
FR
France
Prior art keywords
electronic cigarette
sweetener
liquid
cigarette liquids
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1911826A
Other languages
French (fr)
Other versions
FR3102041A1 (en
Inventor
Chloé Murat
Guillaume Leca
Pierre Ganet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aroma Sens
Original Assignee
Aroma Sens
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aroma Sens filed Critical Aroma Sens
Priority to FR1911826A priority Critical patent/FR3102041B1/en
Priority to EP20203272.8A priority patent/EP3811791A1/en
Publication of FR3102041A1 publication Critical patent/FR3102041A1/en
Application granted granted Critical
Publication of FR3102041B1 publication Critical patent/FR3102041B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/10—Chemical features of tobacco products or tobacco substitutes
    • A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
    • A24B15/167—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes in liquid or vaporisable form, e.g. liquid compositions for electronic cigarettes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Seasonings (AREA)
  • Manufacture Of Tobacco Products (AREA)

Abstract

L’invention concerne une composition destinée à être utilisée comme e-liquide de cigarette électronique ou à être ajoutée à un e-liquide de cigarette électronique, caractérisée en ce qu’elle comprend du N-[N-(3,3-diméthylbutyle)-L-α-aspartyl]-L-phénylalanine 1-ester méthylique, un dispositif de stockage comprenant une telle composition, une cigarette électronique comprenant un tel dispositif et l’utilisation du N-[N-(3,3-diméthylbutyle)-L-α-aspartyl]-L-phénylalanine 1-ester méthylique comme édulcorant ou comme exhausteur de goût dans une composition de e-liquide pour cigarette électronique.The invention relates to a composition intended to be used as an e-liquid for an electronic cigarette or to be added to an e-liquid for an electronic cigarette, characterized in that it comprises N-[N-(3,3-dimethylbutyl)-L-α-aspartyl]-L-phenylalanine 1-methyl ester, a storage device comprising such a composition, an electronic cigarette comprising such a device and the use of N-[N-(3,3-dimethylbutyl)-L-α-aspartyl]-L-phenylalanine 1-methyl ester as a sweetener or as a taste enhancer in an e-liquid composition for an electronic cigarette.

FR1911826A 2019-10-22 2019-10-22 Sweetener for electronic cigarette liquids Active FR3102041B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR1911826A FR3102041B1 (en) 2019-10-22 2019-10-22 Sweetener for electronic cigarette liquids
EP20203272.8A EP3811791A1 (en) 2019-10-22 2020-10-22 Sweetener for electronic cigarette liquids

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1911826A FR3102041B1 (en) 2019-10-22 2019-10-22 Sweetener for electronic cigarette liquids
FR1911826 2019-10-22

Publications (2)

Publication Number Publication Date
FR3102041A1 FR3102041A1 (en) 2021-04-23
FR3102041B1 true FR3102041B1 (en) 2025-02-14

Family

ID=70978001

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1911826A Active FR3102041B1 (en) 2019-10-22 2019-10-22 Sweetener for electronic cigarette liquids

Country Status (2)

Country Link
EP (1) EP3811791A1 (en)
FR (1) FR3102041B1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114009825B (en) * 2021-11-09 2023-04-18 深圳雾芯科技有限公司 Electronic atomized liquid and atomization device comprising same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2719590B1 (en) 1994-05-09 1996-07-26 Claude Nofre Improved process for the preparation of a compound derived from aspartame useful as a sweetening agent.
US5480688A (en) 1994-06-13 1996-01-02 The Auld Company Shaped flexible decorative articles and method for making same
US5728862A (en) 1997-01-29 1998-03-17 The Nutrasweet Company Method for preparing and purifying an N-alkylated aspartame derivative
US6291004B1 (en) 1997-09-11 2001-09-18 The Nutrasweet Company Basic salts of n-[n-(3,3-dimethylbutyl)-l-α-aspartyl]-l-phenylalanine 1-methyl ester
US6146680A (en) 1997-09-11 2000-11-14 The Nutrasweet Company Metal complexes of N-[N-(3,3-dimethylbutyl)-L-α-aspartyl]-L-phenylalanine 1-methyl ester
US6214402B1 (en) 1998-09-17 2001-04-10 The Nutrasweet Company Co-crystallization of sugar and n-[n-(3,3-dimethylbutyl)-l αaspartyl]-l-phenylalanine 1-methyl ester
WO2000069282A1 (en) 1999-05-13 2000-11-23 The Nutrasweet Company Modification of the taste and physicochemical properties of neotame using hydrophobic acid additives
US20030008047A1 (en) 2000-03-17 2003-01-09 Schroeder Steve A. Stability enhancement of sweeteners using salts containing divalent or trivalent cations
GB2535427A (en) * 2014-11-07 2016-08-24 Nicoventures Holdings Ltd Solution
MY189888A (en) * 2016-11-10 2022-03-17 Nicoventures Trading Ltd Tobacco blend
GB2562764A (en) * 2017-05-24 2018-11-28 Robert Hopps Jason Tobacco-containing consumable for aerosol generating devices
EP3574902A1 (en) * 2018-06-01 2019-12-04 Yatzz Limited Nicotine formulation and mode of delivery
CN110215732B (en) 2019-07-16 2021-11-12 山东奔月生物科技股份有限公司 Method for cocrystallization of neotame and erythritol

Also Published As

Publication number Publication date
FR3102041A1 (en) 2021-04-23
EP3811791A1 (en) 2021-04-28

Similar Documents

Publication Publication Date Title
Webster et al. Inflammation and skeletal muscle wasting during cachexia
Schmitz et al. Cathepsin B: Active site mapping with peptidic substrates and inhibitors
Ferrario et al. The ANG-(1–7)/ACE2/mas axis in the regulation of nephron function
Karlsen et al. Postoperative pain treatment after total hip arthroplasty: a systematic review
MA53076B1 (en) SOLID COMPOSITIONS COMPRISING A GLP-1 AGONIST, N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLATE ACID SALT AND A LUBRICANT
Peng et al. Perfluorooctanoic acid alternatives hexafluoropropylene oxides exert male reproductive toxicity by disrupting blood-testis barrier
Canabady-Rochelle et al. Determination of reducing power and metal chelating ability of antioxidant peptides: Revisited methods
Rajagopalan et al. Altered ubiquitin-proteasome signaling in right ventricular hypertrophy and failure
Hall et al. Gastric mucosal mast cells are increased in Helicobacter pylori-negative functional dyspepsia
Hoyer et al. Initial treatment of idiopathic nephrotic syndrome in children: Prednisone: versus: Prednisone Plus Cyclosporine A: A prospective, randomized trial
Peters et al. Carnosine treatment in combination with ACE inhibition in diabetic rats
Janssen et al. Ineffective degradation of immunogenic gluten epitopes by currently available digestive enzyme supplements
Fagyas et al. New perspectives in the renin-angiotensin-aldosterone system (RAAS) II: albumin suppresses angiotensin converting enzyme (ACE) activity in human
MA62173B1 (en) HUMAN ANTI-RANKL ANTIBODY FORMULATIONS AND METHODS OF USE THEREOF
FR3102041B1 (en) Sweetener for electronic cigarette liquids
Kimura et al. KMI-358 and KMI-370, highly potent and small-sized BACE1 inhibitors containing phenylnorstatine
MA52556B1 (en) SOLID COMPOSITIONS COMPRISING A GLP-1 AGONIST AND N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLATE ACID SALT
EP4588938A3 (en) Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies
Streja et al. Management of dyslipidemia in the elderly
Oliveira Andrade et al. The angiotensin converting enzyme 2 (ACE2), gut microbiota, and cardiovascular health
EA202192925A1 (en) SOLID FORMS OF THE GLYT1 INHIBITOR
EA201070746A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING AT LEAST ONE PROTEIN ACTIVE INGREDIENT PROTECTED AGAINST DIVISION INGREDIENT
MA52154B1 (en) Pharmaceutical composition for anemia
Kanodia et al. Dose related efficacy of gabapentin in acute herpetic neuralgia among geriatric patients
Spada et al. Immunogenic potential of beer types brewed with hordeum and triticum spp. malt disclosed by proteomics

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20210423

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7